[smartdoctor] Re: Fw: Re: Afera Pfizer
- From: Dijana RS <dijana.rs1@xxxxxxxxx>
- To: "smartdoctor@xxxxxxxxxxxxx" <smartdoctor@xxxxxxxxxxxxx>
- Date: Mon, 13 Aug 2012 21:24:14 +0200
Ajme... Gledajući ovu emisiju u Krupnom planu jedino što mogu reći je da se
osjećam jadno dok slušam pojedine kolege koji se ponašaju gore nego na placu.
Gdje smo mi od akademskih građana...
Mislim da bi na našem fakultetu trebali uvesti debatu kao obavezni kolegij.
Možda bi naučili uvažavati sudionike u ragovoru koliko god imali oprečne
stavove.
Slušajući svađu kolega izgubila se poanta i glavna tema koja bi trebala biti
izuzetno važna.
A kako tek pojedini kolege lagano proglašava veći dio kolega korumpiranima.
Kad bi i mi mogli naplatiti od pacijenata svoje usluge- možda ne bi trebali
sponzore za stručno usavršavanje.
Sve u svemu-gorak okus nakon ove emisije. I to samo zbog kolega i međusobnog
neuvažavanja.
Lp, Dijana RS
Poslano s mog iPhone uređaja
13. 8. 2012., u 20:22, aleksandar ljubotina <alexandar_ljubotina@xxxxxxxxx>
napisao:
> Veceras u 20.35 na HRT1 "U krupnom planu": Afera Pfizer, ne bi bilo loše
> pogledati!
>
> From: Dr. Jadranka Okmazic <okmazic.jadrankaord.opce.medicine@xxxxxxxxxxx>
> To: smartdoctor@xxxxxxxxxxxxx
> Sent: Friday, August 10, 2012 5:41 PM
> Subject: [smartdoctor] Fw: Re: Afera Pfizer
>
>
> ----- Original Message -----
> From: aleksandar ljubotina
> To: smartdoctor@xxxxxxxxxxxxx
> Sent: Friday, August 10, 2012 12:08 PM
> Subject: [smartdoctor] Re: Afera Pfizer
>
> Hvala ti Jadranka, problem je što javna gladila ne glade SLOM-ove, nego neke
> druge socijalne skupine u RH...ali vrijedi se boriti -
>
> From: J Soic <jsoic@xxxxxxxxx>
> To: Listaaa <smartdoctor@xxxxxxxxxxxxx>
> Sent: Friday, August 10, 2012 11:24 AM
> Subject: [smartdoctor] Re: Afera Pfizer
> Ovaj bih mail objavila u javnim gladilima u ime svih obiteljskih lijecnika.
> Sent from Yahoo! Mail on Android
> From: aleksandar ljubotina <alexandar_ljubotina@xxxxxxxxx>;
> To: smartdoctor@xxxxxxxxxxxxx <smartdoctor@xxxxxxxxxxxxx>;
> Subject: [smartdoctor] Re: Afera Pfizer
> Sent: Fri, Aug 10, 2012 7:56:42 AM
> Dragi svi,
> nekako mi se čini da je farmaceutska tvrtka s dva nježna ženska imena u
> nazivu nadmašila Pfizer, barem u RH: Forteo, Byetta, Zypadhera...uvjeren sam
> da ti lijekovi nisu osvanuli na listi HZZO-a posredovanjem i zaslugom
> obiteljskih liječnika.
>
> Molim da uočite da smo napokon izjednačeni s uglednim profesorima iz
> različitih odbora za lijekove i predstojnicima klinika,ako već ne po
> stručnosti, onda po koruptivnom potencijalu.. Naglasak je na potencijalu, jer
> sumnjam da bilo tko od nas ima inozemne bankovne račune u koje redovito
> mjesečno kapne koja tisućica eura, i pun salon trofeja s afričkih safarija.
> Ako uzmemo da prosječni SLOM propiše lijekova u vrijednosti barem milijun HRK
> godišnje, pa još uzmemo u račun od novinara spominjanih 12%, farmaceutske nam
> kuće duguju barem 2-3 apartmana na moru ( čak i ako odbijemo kemijske,
> ručnike, ruksake i kotizacije za kongrese OM- imamo ih čak četiri godišnje,
> što jasno ukazuje da nam je samo od farmaceutskih tvrtki plaćeni nerad na
> pameti).
>
> Još nešto, gdje su u toj koruptivnoj priči magistre/i farmacije? Novinari
> ili misle da one/i ne igraju tu nikakvu ulogu, ili ih drže prvenstveno
> trgovcima kojima razni rabati i nagradna putovanja spadaju u opis radnog
> mjesta.
>
> Pitanje za medije: Ako nas neka generička firma (takve uglavnom surađuju s
> OM) plaćanjem nekog od kongresa OM motivira na propisivanje njihovih lijekova
> koji su najjeftiniji među paralelama, i na taj način smanjimo HZZ-u troškove
> za desetak posto, je li to baš takav sukob interesa zbog kojega smo zaslužili
> stup srama?
>
> Mislim da bi u ovom trenutku mi kao obiteljski liječnici trebali odigrati
> proaktivan potez prema farmaceustkim tvrtkama, a zašto ne i prema HZZO-u, sa
> zahtjevom da većinu stručnih predavanja za obiteljske drže obiteljski
> liječnici, uz honorar daleko niži od bolničkih kolega, a razliku bi
> farmaceutske kuće mogle transparentno uložiti u fond za opremanje ambulanti.
> Time bi javnosti pokazali da nam je temeljni cilj pružanje što kvalitetnije
> usluge svojim pacijentima, a jedini način "bogaćenja" bio bi preko DTP
> postupaka (delimitiranih) koje bi odrađivali uz pomoć te opreme (koja može
> biti i u vlasništvu HZZO-a, da je slučajno ne bi preprodavali na "crnom"
> tržištu).
>
>
> Pozdrav, Saša
>
>
>
>
>
>
> From: Leonardo Bressan <ordinacija.dr.leonardo.bressan@xxxxxxxxx>
> To: smartdoctor@xxxxxxxxxxxxx
> Sent: Friday, August 10, 2012 8:48 AM
> Subject: [smartdoctor] Afera Pfizer
> SEC Charges Pfizer with FCPA Violations
>
> FOR IMMEDIATE RELEASE
> 2012-152
> Washington, D.C., Aug. 7, 2012 – The Securities and Exchange Commission today
> charged Pfizer Inc. with violating the Foreign Corrupt Practices Act (FCPA)
> when its subsidiaries bribed doctors and other health care professionals
> employed by foreign governments in order to win business.
> The SEC alleges that employees and agents of Pfizer’s subsidiaries in
> Bulgaria, China, Croatia, Czech Republic, Italy, Kazakhstan, Russia, and
> Serbia made improper payments to foreign officials to obtain regulatory and
> formulary approvals, sales, and increased prescriptions for the company’s
> pharmaceutical products. They tried to conceal the bribery by improperly
> recording the transactions in accounting records as legitimate expenses for
> promotional activities, marketing, training, travel and entertainment,
> clinical trials, freight, conferences, and advertising.
> Additional Materials
>
> SEC Complaint Against Pfizer
> SEC Complaint Against Wyeth
> More SEC FCPA Cases
> The SEC separately charged another pharmaceutical company that Pfizer
> acquired a few years ago – Wyeth LLC – with its own FCPA violations. Pfizer
> and Wyeth agreed to separate settlements in which they will pay more than $45
> million combined to settle their respective charges. In a parallel action,
> the Department of Justice announced that Pfizer H.C.P. Corporation agreed to
> pay a $15 million penalty to resolve its investigation of FCPA violations.
> “Pfizer subsidiaries in several countries had bribery so entwined in their
> sales culture that they offered points and bonus programs to improperly
> reward foreign officials who proved to be their best customers,” said Kara
> Brockmeyer, Chief of the SEC Enforcement Division’s Foreign Corrupt Practices
> Act Unit. “These charges illustrate the pitfalls that exist for companies
> that fail to appropriately monitor potential risks in their global
> operations.”
> According to the SEC’s complaint against Pfizer filed in U.S. District Court
> for the District of Columbia, the misconduct dates back as far as 2001.
> Employees of Pfizer’s subsidiaries authorized and made cash payments and
> provided other incentives to bribe government doctors to utilize Pfizer
> products. In China, for example, Pfizer employees invited “high-prescribing
> doctors” in the Chinese government to club-like meetings that included
> extensive recreational and entertainment activities to reward doctors’ past
> product sales or prescriptions. Pfizer China also created various “point
> programs” under which government doctors could accumulate points based on the
> number of Pfizer prescriptions they wrote. The points were redeemed for
> various gifts ranging from medical books to cell phones, tea sets, and
> reading glasses. In Croatia, Pfizer employees created a “bonus program” for
> Croatian doctors who were employed in senior positions in Croatian government
> health care institutions. Once a doctor agreed to use Pfizer products, a
> percentage of the value purchased by a doctor’s institution would be funneled
> back to the doctor in the form of cash, international travel, or free
> products.
> According to the SEC’s complaint, Pfizer made an initial voluntary disclosure
> of misconduct by its subsidiaries to the SEC and Department of Justice in
> October 2004, and fully cooperated with SEC investigators. Pfizer took such
> extensive remedial actions as undertaking a comprehensive worldwide review of
> its compliance program.
> The SEC further alleges that Wyeth subsidiaries engaged in FCPA violations
> primarily before but also after the company’s acquisition by Pfizer in late
> 2009. Starting at least in 2005, subsidiaries marketing Wyeth nutritional
> products in China, Indonesia, and Pakistan bribed government doctors to
> recommend their products to patients by making cash payments or in some cases
> providing BlackBerrys and cell phones or travel incentives. They often used
> fictitious invoices to conceal the true nature of the payments. In Saudi
> Arabia, Wyeth’s subsidiary made an improper cash payment to a customs
> official to secure the release of a shipment of promotional items used for
> marketing purposes. The promotional items were held in port because Wyeth
> Saudi Arabia had failed to secure a required Saudi Arabian Standards
> Organization Certificate of Conformity.
> Following Pfizer’s acquisition of Wyeth, Pfizer undertook a risk-based FCPA
> due diligence review of Wyeth’s global operations and voluntarily reported
> the findings to the SEC staff. Pfizer diligently and promptly integrated
> Wyeth’s legacy operations into its compliance program and cooperated fully
> with SEC investigators.
> In settling the SEC’s charges, Wyeth neither admitted nor denied the
> allegations. Pfizer consented to the entry of a final judgment ordering it to
> pay disgorgement of $16,032,676 in net profits and prejudgment interest of
> $10,307,268 for a total of $26,339,944. Wyeth also is required to report to
> the SEC on the status of its remediation and implementation of compliance
> measures over a two-year period, and is permanently enjoined from further
> violations of Sections 13(b)(2)(A) and 13(b)(2)(B) of the Securities Exchange
> Act of 1934. Wyeth consented to the entry of a final judgment ordering it to
> pay disgorgement of $17,217,831 in net profits and prejudgment interest of
> $1,658,793, for a total of $18,876,624. As a Pfizer subsidiary, the status of
> Wyeth’s remediation and implementation of compliance measures will be
> subsumed in Pfizer’s two-year self-reporting period. Wyeth also is
> permanently enjoined from further violations of Sections 13(b)(2)(A) and
> 13(b)(2)(B) of the Exchange Act. The settlements are subject to court
> approval.
> The SEC’s investigation was conducted by Michael Catoe and Charles Cain of
> the Enforcement Division’s FCPA Unit. The SEC acknowledges the assistance of
> the U.S. Department of Justice’s Criminal Division’s Fraud Section and the
> Federal Bureau of Investigation in this matter.
> # # #
> http://www.sec.gov/news/press/2012/2012-152.htm
> __________ NOD32 2604 (20071019) Informacija __________Ova je poruka
> provjerena NOD32 antivirusnim sistemom.http://www.nod32.com.hr/
Other related posts:
